Abstract
Objective: Our aim was evaluate the relationship between 25-Hydroxyvitamin D (25(OH)D) and old and new generation anti-seizure drugs (ASDs), seizure type and seizure frequency in epilepsy patients.
 Method: A total of 96 individuals aged 18 years and older with epilepsy were included in this study who were followed up in the SBU Adana City Training and Research Hospital Epilepsy outpatient clinic between January 1, 2020 and November 1, 2022 and met the inclusion criteria. Patients were grouped by age, gender, seizure type, frequency, and ASDs usage (according to their relationship with cytochrome P450 enzymes). Complete blood count, kidney functions, serum ASD levels and calcium, magnesium, phosphate and parathormone levels, season when 25(OH)D were measured, and sun exposure time was also obtained from patient file scans.
 Results: 55.2% of the patients were women and the mean age was 32.56±12.90 (Min:18 Max:71). 25(OH)D level was found to be deficient or insufficient in 95.8% of the patients. The 25(OH)D level was statistically significantly lower in patients with generalized and complex partial epilepsy who were exposed to the sun for less than one hour per week compared to the focal type and those exposed to the sun for more than one hour per week. p
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
